Skip to main content

Articles

Page 1 of 66

  1. The advent of PD1/PD-L1 inhibitors has significantly transformed the therapeutic landscape for clear cell renal cell carcinoma (ccRCC). This review provides an in-depth analysis of the biological functions and...

    Authors: Zhaoyang Zhu, Yigang Jin, Jing Zhou, Fei Chen, Minjie Chen, Zhaofeng Gao, Lingyu Hu, Jinyan Xuan, Xiaoping Li, Zhengwei Song and Xiao Guo
    Citation: Molecular Cancer 2024 23:146
  2. Diffuse large B-cell lymphoma (DLBCL) represents a prevalent malignant tumor, with approximately 40% of patients encountering treatment challenges or relapse attributed to rituximab resistance, primarily due t...

    Authors: Xin Wu, Chunmei Ban, Woding Deng, Xuewei Bao, Ning Tang, Yupeng Wu, Zhixuan Deng, Jianbin Xiong and Qiangqiang Zhao
    Citation: Molecular Cancer 2024 23:144
  3. Emerging evidence indicates the pivotal involvement of circular RNAs (circRNAs) in cancer initiation and progression. Understanding the functions and underlying mechanisms of circRNAs in tumor development hold...

    Authors: Yang Ji, Chuangye Ni, Yanjun Shen, Zhenggang Xu, Lei Tang, Fei Yu, Lingbang Zhu, Hao Lu, Chuanyong Zhang, Shikun Yang and Xuehao Wang
    Citation: Molecular Cancer 2024 23:143
  4. Breast cancer (BC) is the most common cancer in women, with triple negative BC (TNBC) accounting for 20% of cases. While early detection and targeted therapies have improved overall life expectancy, TNBC remai...

    Authors: Claudia Cifuentes, Clara L. Oeste, Isabel Fernández-Pisonero, Alejandro M. Hortal, Carmen García-Macías, Jeanne Hochart, Regina Rubira, Lydia Horndler, Carlos Horndler, Xosé R. Bustelo and Balbino Alarcón
    Citation: Molecular Cancer 2024 23:142
  5. The aberrant expression of phosphofructokinase-platelet (PFKP) plays a crucial role in the development of various human cancers by modifying diverse biological functions. However, the precise molecular mechani...

    Authors: Weiwei Liu, Zhao Ding, Ye Tao, Shixian Liu, Maoyu Jiang, Fangzheng Yi, Zixi Wang, Yanxun Han, Huaiyuan Zong, Dapeng Li, Yue Zhu, Zihui Xie, Shujia Sang, Xixi Chen, Manli Miao, Xu Chen…
    Citation: Molecular Cancer 2024 23:141
  6. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis and limited therapeutic options. Research on the tumor microenvironment (TME) of PDAC has propelled the developme...

    Authors: Yifan Fu, Jinxin Tao, Tao Liu, Yueze Liu, Jiangdong Qiu, Dan Su, Ruobing Wang, Wenhao Luo, Zhe Cao, Guihu Weng, Taiping Zhang and Yupei Zhao
    Citation: Molecular Cancer 2024 23:140
  7. Radioresistance is the leading cause of death in advanced cervical cancer (CC). Dysregulation of RNA modification has recently emerged as a regulatory mechanism in radiation and drug resistance. We aimed to ex...

    Authors: Min Yu, Mengdong Ni, Fei Xu, Chaohua Liu, Lihua Chen, Jiana Li, Siyu Xia, Yixin Diao, Jiaxin Chen, Jun Zhu, Xiaohua Wu, Min Tang, Jiajia Li and Guihao Ke
    Citation: Molecular Cancer 2024 23:139
  8. The BCR::ABL1 is a hallmark of chronic myeloid leukemia (CML) and is also found in acute lymphoblastic leukemia (ALL). Most genomic breaks on the BCR side occur in two regions - Major and minor - leading to p210 ...

    Authors: Lenka Hovorkova, Lucie Winkowska, Justina Skorepova, Manuela Krumbholz, Adela Benesova, Vaclava Polivkova, Julia Alten, Michela Bardini, Claus Meyer, Rathana Kim, Toby N. Trahair, Emmanuelle Clappier, Sabina Chiaretti, Michelle Henderson, Rosemary Sutton, Lucie Sramkova…
    Citation: Molecular Cancer 2024 23:138
  9. The outcome of hepatocellular carcinoma (HCC) is limited by its complex molecular characteristics and changeable tumor microenvironment (TME). Here we focused on elucidating the functional consequences of Mate...

    Authors: Bufu Tang, Jinyu Zhu, Yueli Shi, Yajie Wang, Xiaojie Zhang, Biao Chen, Shiji Fang, Yang Yang, Liyun Zheng, Rongfang Qiu, Qiaoyou Weng, Min Xu, Zhongwei Zhao, Jianfei Tu, Minjiang Chen and Jiansong Ji
    Citation: Molecular Cancer 2024 23:137
  10. BRAF inhibitors are widely employed in the treatment of melanoma with the BRAF V600E mutation. However, the development of resistance compromises their therapeutic efficacy. Diverse genomic and transcriptomic ...

    Authors: Byung-Sun Park, Heeju Jeon, Yeonseo Kim, Haejin Kwon, Ga-Eun Choi, Sung-Gil Chi, Hyun-Mee Park, Hyunbeom Lee and Tackhoon Kim
    Citation: Molecular Cancer 2024 23:136
  11. In cells, signal transduction heavily relies on the intricate regulation of protein kinases, which provide the fundamental framework for modulating most signaling pathways. Dysregulation of kinase activity has...

    Authors: Javad Karimbayli, Ilenia Pellarin, Barbara Belletti and Gustavo Baldassarre
    Citation: Molecular Cancer 2024 23:135
  12. Metastatic colorectal cancer (mCRC) presents significant challenges in clinical management due to its heterogeneity and variable response to treatment. In this study, we conducted comprehensive small RNA (sRNA...

    Authors: Robin Mjelle, Are K. Kristensen, Tora S. Solheim, Ganna S. Westvik, Hege Elvebakken and Eva Hofsli
    Citation: Molecular Cancer 2024 23:133
  13. TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare but highly heterogeneous renal cell carcinoma (RCC) entity, of which the clinical treatment landscape is largely undefined. This study aims to evaluate a...

    Authors: Junjie Zhao, Yanfeng Tang, Xu Hu, Xiaoxue Yin, Yuntian Chen, Junru Chen, Haoyang Liu, Haolin Liu, Jiayu Liang, Xingming Zhang, Jinge Zhao, Sha Zhu, Yuchao Ni, Zhipeng Wang, Jindong Dai, Zilin Wang…
    Citation: Molecular Cancer 2024 23:132
  14. Tumor immune microenvironment (TIME) consists of intra-tumor immunological components and plays a significant role in tumor initiation, progression, metastasis, and response to therapy. Chimeric antigen recept...

    Authors: Zhaokai Zhou, Jiahui Wang, Jiaojiao Wang, Shuai Yang, Ruizhi Wang, Ge Zhang, Zhengrui Li, Run Shi, Zhan Wang and Qiong Lu
    Citation: Molecular Cancer 2024 23:131
  15. Malignant tumors have increasing morbidity and high mortality, and their occurrence and development is a complicate process. The development of sequencing technologies enabled us to gain a better understanding...

    Authors: Yang Jin, Yuanli Zuo, Gang Li, Wenrong Liu, Yitong Pan, Ting Fan, Xin Fu, Xiaojun Yao and Yong Peng
    Citation: Molecular Cancer 2024 23:129
  16. Circular RNAs (circRNAs) play important roles in cancer progression and metastasis. However, the expression profiles and biological roles of circRNAs in non-small cell lung cancer (NSCLC) remain unclear.

    Authors: Maoye Wang, Xiaoge Ding, Xinjian Fang, Jing Xu, Yanke Chen, Yu Qian, Jiahui Zhang, Dan Yu, Xiaoxin Zhang, Xiuqin Ma, Taofeng Zhu, Jianmei Gu and Xu Zhang
    Citation: Molecular Cancer 2024 23:128
  17. The clinical heterogeneity of early-stage endometrial cancer (EC) is worthy of further study to identify high-quality prognostic markers and their potential role in aggressive tumor behavior. Mutation of TP53 ...

    Authors: Xiaodan Mao, Xiaoyue Tang, Jingxuan Ye, Shuxia Xu, Yue Wang, Xianhua Liu, Qibin Wu, Xite Lin, Maotong Zhang, Jiangfeng Liu, Juntao Yang and Pengming Sun
    Citation: Molecular Cancer 2024 23:127
  18. In an extensive genomic analysis of lung adenocarcinomas (LUADs), driver mutations have been recognized as potential targets for molecular therapy. However, there remain cases where target genes are not identi...

    Authors: Syuzo Kaneko, Ken Takasawa, Ken Asada, Kouya Shiraishi, Noriko Ikawa, Hidenori Machino, Norio Shinkai, Maiko Matsuda, Mari Masuda, Shungo Adachi, Satoshi Takahashi, Kazuma Kobayashi, Nobuji Kouno, Amina Bolatkan, Masaaki Komatsu, Masayoshi Yamada…
    Citation: Molecular Cancer 2024 23:126
  19. Platinum resistance is the primary cause of poor survival in ovarian cancer (OC) patients. Targeted therapies and biomarkers of chemoresistance are critical for the treatment of OC patients. Our previous studi...

    Authors: Rashmi Bharti, Goutam Dey, Debjit Khan, Alex Myers, Olivia G. Huffman, Caner Saygin, Chad Braley, Elliott Richards, Naseer Sangwan, Belinda Willard, Justin D. Lathia, Paul L. Fox, Feng Lin, Babal Kant Jha, J. Mark Brown, Jennifer S. Yu…
    Citation: Molecular Cancer 2024 23:121
  20. Breast cancer is the most common malignant tumor, and metastasis remains the major cause of poor prognosis. Glucose metabolic reprogramming is one of the prominent hallmarks in cancer, providing nutrients and ...

    Authors: Yiran Liang, Fangzhou Ye, Dan Luo, Li Long, Yajie Wang, Yuhan Jin, Lei Wang, Yaming Li, Dianwen Han, Bing Chen, Wenjing Zhao, Lijuan Wang and Qifeng Yang
    Citation: Molecular Cancer 2024 23:125
  21. Intestinal metaplasia (IM) is classified into complete intestinal metaplasia (CIM) and incomplete intestinal metaplasia (IIM). Patients diagnosed with IIM face an elevated susceptibility to the development of ...

    Authors: Hongfa Wei, Wenchao Li, Leli Zeng, Ni Ding, Kuan Li, Hong Yu, Fei Jiang, Haofan Yin, Yu Xia, Cuncan Deng, Nan Cai, Xiancong Chen, Liang Gu, Huanjie Chen, Feiran Zhang, Yulong He…
    Citation: Molecular Cancer 2024 23:124
  22. Pediatric-type diffuse high-grade glioma (pHGG) is the most frequent malignant brain tumor in children and can be subclassified into multiple entities. Fusion genes activating the MET receptor tyrosine kinase ...

    Authors: Marc Zuckermann, Chen He, Jared Andrews, Aditi Bagchi, Roketa Sloan-Henry, Brandon Bianski, Jia Xie, Yingzhe Wang, Nathaniel Twarog, Arzu Onar-Thomas, Kati J. Ernst, Lei Yang, Yong Li, Xiaoyan Zhu, Jennifer K. Ocasio, Kaitlin M. Budd…
    Citation: Molecular Cancer 2024 23:123
  23. Metastasis remains the principal cause of cancer-related lethality despite advancements in cancer treatment. Dysfunctional epigenetic alterations are crucial in the metastatic cascade. Among these, super-enhan...

    Authors: Shenglan Liu, Wei Dai, Bei Jin, Feng Jiang, Hao Huang, Wen Hou, Jinxia Lan, Yanli Jin, Weijie Peng and Jingxuan Pan
    Citation: Molecular Cancer 2024 23:122
  24. The efficacy of anthracycline-based chemotherapeutics, which include doxorubicin and its structural relatives daunorubicin and idarubicin, remains almost unmatched in oncology, despite a side effect profile in...

    Authors: Xiaohang Qiao, Sabina Y. van der Zanden, Xiaoyang Li, Minkang Tan, Yunxiang Zhang, Ji-Ying Song, Merle A. van Gelder, Feija L. Hamoen, Lennert Janssen, Charlotte L. Zuur, Baoxu Pang, Olaf van Tellingen, Junmin Li and Jacques Neefjes
    Citation: Molecular Cancer 2024 23:120
  25. Triple negative breast cancer (TNBC) remains exceptionally challenging to treat. While CDK4/6 inhibitors have revolutionized HR + breast cancer therapy, there is limited understanding of their efficacy in TNBC...

    Authors: Sophie Poulet, Meiou Dai, Ni Wang, Gang Yan, Julien Boudreault, Girija Daliah, Alan Guillevin, Huong Nguyen, Soaad Galal, Suhad Ali and Jean-Jacques Lebrun
    Citation: Molecular Cancer 2024 23:118
  26. Significant advancements have been made in the application of chimeric antigen receptor (CAR)-T treatment for blood cancers during the previous ten years. However, its effectiveness in treating solid tumors is...

    Authors: Na Li, Shinan Geng, Zhen-zhen Dong, Ying Jin, Hangjie Ying, Hung-Wing Li and Liyun Shi
    Citation: Molecular Cancer 2024 23:117
  27. Elevated evidence suggests that the SENPs family plays an important role in tumor progression. However, the role of SENPs in AML remains unclear.

    Authors: Diguang Wen, Hang Xiao, Yueyi Gao, Hanqing Zeng and Jianchuan Deng
    Citation: Molecular Cancer 2024 23:116
  28. We explored potential predictive biomarkers of immunotherapy response in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + tremelimumab (T) + etoposide-platinum (EP),...

    Authors: Mingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, Johannes Zimmermann, Markus Schick, Cathy O’Brien, Luis Paz-Ares, Jonathan W. Goldman, Marina Chiara Garassino, Carl M. Gay, John V. Heymach, Haiyi Jiang, J. Carl Barrett, Ross A. Stewart, Zhongwu Lai, Lauren A. Byers…
    Citation: Molecular Cancer 2024 23:115
  29. Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated ...

    Authors: Torben Redmer, Martin Raigel, Christina Sternberg, Roman Ziegler, Clara Probst, Desiree Lindner, Astrid Aufinger, Tanja Limberger, Karolina Trachtova, Petra Kodajova, Sandra Högler, Michaela Schlederer, Stefan Stoiber, Monika Oberhuber, Marco Bolis, Heidi A. Neubauer…
    Citation: Molecular Cancer 2024 23:114
  30. The role of circRNAs in hepatocellular carcinoma (HCC) progression remains unclear. CircPIAS1 (circBase ID: hsa_circ_0007088) was identified as overexpressed in HCC cases through bioinformatics analysis. This ...

    Authors: Xiao-Yu Zhang, Shan-Shan Li, Yu-Rong Gu, Le-Xin Xiao, Xin-Yi Ma, Xin-Ru Chen, Jia-Liang Wang, Chun-Hong Liao, Bing-Liang Lin, Yue-Hua Huang and Yi-Fan Lian
    Citation: Molecular Cancer 2024 23:113
  31. Poly (ADP-ribose) polymerase inhibitor (PARPi) resistance poses a significant challenge in ovarian carcinoma (OC). While the role of DOT1L in cancer and chemoresistance is acknowledged, its specific role in PA...

    Authors: Chaohua Liu, Jiana Li, Fei Xu, Lihua Chen, Mengdong Ni, Jiangchun Wu, Haiyun Zhao, Yangjun Wu, Jiajia Li, Xiaohua Wu and Xiaojun Chen
    Citation: Molecular Cancer 2024 23:111
  32. Breast cancer (BC) is the most frequent malignant cancer diagnosis and is a primary factor for cancer deaths in women. The clinical subtypes of BC include estrogen receptor (ER) positive, progesterone receptor...

    Authors: Chang-Yun Li, Wanhe Wang, Chung-Hang Leung, Guan-Jun Yang and Jiong Chen
    Citation: Molecular Cancer 2024 23:109
  33. Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. The programmed death protein...

    Authors: Xin Lin, Kuan Kang, Pan Chen, Zhaoyang Zeng, Guiyuan Li, Wei Xiong, Mei Yi and Bo Xiang
    Citation: Molecular Cancer 2024 23:108
  34. Neutrophils play a Janus-faced role in the complex landscape of cancer pathogenesis and immunotherapy. As immune defense cells, neutrophils release toxic substances, including reactive oxygen species and matri...

    Authors: Xueqin Huang, Eugenie Nepovimova, Vojtech Adam, Ladislav Sivak, Zbynek Heger, Marian Valko, Qinghua Wu and Kamil Kuca
    Citation: Molecular Cancer 2024 23:107
  35. Aging and cancer exhibit apparent links that we will examine in this review. The null hypothesis that aging and cancer coincide because both are driven by time, irrespective of the precise causes, can be confr...

    Authors: Léa Montégut, Carlos López-Otín and Guido Kroemer
    Citation: Molecular Cancer 2024 23:106
  36. The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to assess...

    Authors: Luca Ponzone, Valentina Audrito, Claudia Landi, Enrico Moiso, Chiara Levra Levron, Sara Ferrua, Aurora Savino, Nicoletta Vitale, Massimiliano Gasparrini, Lidia Avalle, Lorenza Vantaggiato, Enxhi Shaba, Beatrice Tassone, Stefania Saoncella, Francesca Orso, Daniele Viavattene…
    Citation: Molecular Cancer 2024 23:105
  37. The faithful maintenance of DNA methylation homeostasis indispensably requires DNA methyltransferase 1 (DNMT1) in cancer progression. We previously identified DNMT1 as a potential candidate target for oral squ...

    Authors: Yangfan Liu, Yu Sun, Jin Yang, Deyang Wu, Shuang Yu, Junjiang Liu, Tao Hu, Jingjing Luo and Hongmei Zhou
    Citation: Molecular Cancer 2024 23:104
  38. Pancreatic ductal adenocarcinoma (PDAC) is marked by a dismal survival rate, lacking effective therapeutics due to its aggressive growth, late-stage diagnosis, and chemotherapy resistance. Despite debates on N...

    Authors: Miltiadis Tsesmelis, Ulrike F. G. Büttner, Melanie Gerstenlauer, Uta Manfras, Konstantinos Tsesmelis, Ziwei Du, Nadine Sperb, Stephanie Ellen Weissinger, Peter Möller, Thomas F. E. Barth, Harald J. Maier, Lap Kwan Chan and Thomas Wirth
    Citation: Molecular Cancer 2024 23:103
  39. Peptides and proteins encoded by noncanonical open reading frames (ORFs) of circRNAs have recently been recognized to play important roles in disease progression, but the biological functions and mechanisms of...

    Authors: Yaming Li, Zekun Wang, Jingwen Yang, Yuhan Sun, Yinqiao He, Yuping Wang, Xi Chen, Yiran Liang, Ning Zhang, Xiaolong Wang, Wenjing Zhao, Guohong Hu and Qifeng Yang
    Citation: Molecular Cancer 2024 23:102
  40. Long noncoding RNAs (lncRNAs) have surpassed the number of protein-coding genes, yet the majority have no known function. We previously discovered 844 lncRNAs that were genetically linked to breast cancer thro...

    Authors: Lu Wang, Mainá Bitar, Xue Lu, Sebastien Jacquelin, Sneha Nair, Haran Sivakumaran, Kristine M. Hillman, Susanne Kaufmann, Rebekah Ziegman, Francesco Casciello, Harsha Gowda, Joseph Rosenbluh, Stacey L. Edwards and Juliet D. French
    Citation: Molecular Cancer 2024 23:101
  41. Authors: Xiangyu Jian, Han He, Jiehong Zhu, Qi Zhang, Zhongxin Zheng, Xiangjing Liang, Liuyan Chen, Meiling Yang, Kaiyue Peng, Zhaowen Zhang, Tengfei Liu, Yaping Ye, Hongli Jiao, Shuyang Wang, Weijie Zhou, Yanqing Ding…
    Citation: Molecular Cancer 2024 23:100

    The original article was published in Molecular Cancer 2020 19:20

  42. DLL3 acts as an inhibitory ligand that downregulates Notch signaling and is upregulated by ASCL1, a transcription factor prevalent in the small-cell lung cancer (SCLC) subtype SCLC-A. Currently, the therapeuti...

    Authors: Po-Lan Su, Karthik Chakravarthy, Naoki Furuya, Jeremy Brownstein, Jianhua Yu, Meixiao Long, David Carbone, Zihai Li and Kai He
    Citation: Molecular Cancer 2024 23:97
  43. Accurate presurgical prediction of pathological complete response (pCR) can guide treatment decisions, potentially avoiding unnecessary surgeries and improving the quality of life for cancer patients. We devel...

    Authors: Pinli Yue, Fenglong Bie, Jiarun Zhu, Lin-Rui Gao, Zhendiao Zhou, Guangyu Bai, Xiaobing Wang, Ziyi Zhao, Ze-Fen Xiao, Yong Li, Aiping Zhou, Wen-Yang Liu, Yuchen Jiao and Shugeng Gao
    Citation: Molecular Cancer 2024 23:96

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 27.7
    5-year Journal Impact Factor: 31.3
    Source Normalized Impact per Paper (SNIP): 4.737
    SCImago Journal Rank (SJR): 8.222

    Speed 2023
    Submission to first editorial decision (median days): 3
    Submission to acceptance (median days): 91

    Usage 2023
    Downloads: 3,569,666
    Altmetric mentions: 2,070